-
International Journal of Cardiology Oct 2013To investigate the overall sexual functioning and disease specific sexual problems in congenital heart disease (ConHD) patients, for both genders and different cardiac...
BACKGROUND
To investigate the overall sexual functioning and disease specific sexual problems in congenital heart disease (ConHD) patients, for both genders and different cardiac diagnostic groups, and compare these with Dutch normative data. Also disease specific sexual problems were investigated.
METHODS
From a longitudinal cohort of patients, operated for ConHD between 1968 and 1980, 254 patients (median age: 40, 53.4% male) were included in this study: atrial septal defect (n = 72), ventricular septal defect (n = 71), pulmonary stenosis (n = 30), tetralogy of Fallot (n = 53) and transposition of the great arteries (n = 28). Patients completed internationally validated, generic questionnaires and also disease specific instruments on sexual functioning.
RESULTS
Patients showed a delay in starting sexual activities compared with peers. Females with ConHD scored significantly worse compared with normative data on all scales of sexual functioning, indicating a broad range of sexual problems and 15% showed clinical levels of sexual dysfunction. Of the males, 14% suffered from erectile dysfunction. Males with ConHD scored worse on erectile function, orgasmic function and satisfaction regarding their sexual life compared with normative data. No differences were found between the different cardiac diagnoses. The majority of patients reported disease specific worries and fears about the use of contraceptives, heredity, pregnancy and delivery. Patients indicated to have been suboptimally informed about sexuality in early adolescence.
CONCLUSIONS
This study shows that sexual functioning is impaired in adults with ConHD. Providing information to patients about sexuality, pregnancy, delivery and heredity should be improved, and given at young age.
Topics: Adult; Cohort Studies; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Longitudinal Studies; Male; Middle Aged; Pregnancy; Sexual Behavior; Sexual Dysfunction, Physiological; Surveys and Questionnaires
PubMed: 23859255
DOI: 10.1016/j.ijcard.2013.06.029 -
Journal of the Neurological Sciences Aug 2013Sexual problems are prevalently experienced by women with multiple sclerosis (MS) and have been investigated in several studies. The nature of sexual changes in MS is...
BACKGROUND
Sexual problems are prevalently experienced by women with multiple sclerosis (MS) and have been investigated in several studies. The nature of sexual changes in MS is best defined as primary, secondary, and tertiary.
OBJECTIVES
The aim of this study was to investigate three levels of sexual problems (SP) in female patients with MS and to examine their relationship with various clinical and demographic variables.
METHODS
A total of 132 women with MS completed two questionnaires; demographic and clinical history, and Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 (MSISQ-19). Fatigue was evaluated by Fatigue (energy) sub-scale of Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire. General physical ability and frequency of sexual intercourse were also evaluated.
RESULTS
One hundred and fifteen patients (87.1%) reported primary SP. The most frequent symptoms of primary, secondary and tertiary sexual problems were delayed orgasm, spasticity and concern about partner's sexual satisfaction, respectively. The MSISQ-19 total score was correlated with age(p=0.002), disease duration(p=0.010), marriage duration(p=0.001), fatigue(p<0.001), number of children(p=0.006), physical ability(p<0.001), education(p=0.006), economic status(p=0.002), number of times having sexual intercourse(p=0.007) and number of times approached by spouse for intercourse(p=0.012) in the last 30 days.
CONCLUSIONS
Sexual problems were prevalent among our participants. Appropriate management of SP depends on understanding the disturbed level.
Topics: Adult; Analysis of Variance; Female; Humans; Middle Aged; Multiple Sclerosis; Outcome Assessment, Health Care; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Statistics as Topic; Surveys and Questionnaires; Young Adult
PubMed: 23764363
DOI: 10.1016/j.jns.2013.05.014 -
Acta Poloniae Pharmaceutica 2013The present study aimed to investigate the effect of ethyl acetate fraction of A. cepa bulb on mating behavior in paroxetine-induced sexually dysfunction male rats....
The present study aimed to investigate the effect of ethyl acetate fraction of A. cepa bulb on mating behavior in paroxetine-induced sexually dysfunction male rats. Sexual dysfunctions such as decreased libido, delayed orgasm, difficulties in maintaining an erection, and inhibition of ejaculation are common side effects of paroxetine. A. cepa bulb ethyl acetate fraction (200 mg/kg) was administered orally in paroxetine-induced sexually impaired male rats for 7 days. At the end of 7th day, mount frequency (MF), intromission frequency (IF), ejaculatory frequency (EF), mount latency (ML), intromission latency (IL), ejaculatory latency (EL) and post-ejaculatory interval (PEI) were the parameters observed. Results showed that in relation to the paroxetine treated group, ethyl acetate fraction, significantly restored the normal sexual behavior as evident from increased MF, IF, EF and reduced ML, IL, EL and PEI.
Topics: Acetates; Animals; Disease Models, Animal; Ejaculation; Female; Libido; Male; Onions; Paroxetine; Plant Extracts; Plant Roots; Plants, Medicinal; Rats; Rats, Wistar; Reaction Time; Sexual Behavior, Animal; Sexual Dysfunction, Physiological; Solvents; Time Factors
PubMed: 23614288
DOI: No ID Found -
Clinics (Sao Paulo, Brazil) 2011Orgasmic dysfunction in women is characterized by persistent or recurrent delay in or absence of orgasm following a normal sexual excitement phase. Research has shown...
INTRODUCTION
Orgasmic dysfunction in women is characterized by persistent or recurrent delay in or absence of orgasm following a normal sexual excitement phase. Research has shown that almost two thirds of women have concerns about their sexual relationship. Sexual dysfunction has many problems for couples; some researchers found that up to 67% of divorces related to sexual disorders.
OBJECTIVE
The aim of this cross-sectional study was to assess the prevalence and related factors of anorgasmia among reproductive age Iranian women.
METHODS
This study was conducted in 2006-7 in Hesarak, Karaj, Iran. A total of 1200 women were randomly recruited to the study. Sexual satisfaction questions were prepared according to the Enrich Sexual Satisfaction Questionnaire. Orgasms were assessed according to the relevant questions in the Female Sexual Function Index (FSFI) questionnaire. The data were analyzed using SPSS version 11; Chi-square, Mann-Whitney and independent t-test were used for statistical purposes.
RESULTS
This study showed that the prevalence of anorgasmia among Iranian women in Hesarak, Karaj, was 26.3%. There was a significant difference between the anorgasmic and normal orgasm groups regarding the women's age, age at marriage, duration of marriage and education during puberty (p<0.05). Some psychological factors, e.g. anxiety, fatigue, pain, feeling of guilt, anti-masculine feelings and embarrassment in sexual relationships were higher in the anorgasmic group (p<0.001).
DISCUSSION
The results of this study showed that the prevalence of anorgasmia in Hesarak is high and most of the anorgasmic women were highly unsatisfied with their sexual relationship compared to the normal orgasm group.
CONCLUSION
The prevalence of anorgasmia among Iranian women in Hesarak, Karaj, is high and some socio-demographic and psychological factors have a strong relationship with anorgasmia.
Topics: Adolescent; Adult; Age Factors; Case-Control Studies; Cross-Sectional Studies; Female; Humans; Iran; Middle Aged; Orgasm; Personal Satisfaction; Prevalence; Risk Factors; Sexual Behavior; Sexual Dysfunctions, Psychological; Socioeconomic Factors; Statistics, Nonparametric; Surveys and Questionnaires; Young Adult
PubMed: 21437441
DOI: 10.1590/s1807-59322011000100015 -
Pharmacology, Biochemistry, and Behavior May 2011While selective serotonin reuptake inhibitors (SSRIs) are widely used to treat anxiety and depression, they also produce profound disruptions of sexual function...
While selective serotonin reuptake inhibitors (SSRIs) are widely used to treat anxiety and depression, they also produce profound disruptions of sexual function including delayed orgasm/ejaculation. The nucleus paragigantocellularis (nPGi), a primary source of inhibition of ejaculation in male rats, contains receptors for serotonin (5-HT). The ventrolateral periaqueductal gray (vlPAG) provides serotonin to this region, thus providing an anatomical and neurochemical basis for serotonergic regulation of the nPGi. We hypothesize that 5-HT acting at the nPGi could underlie the SSRI-induced inhibition of ejaculation in rodents. To this end, we produced 5-HT lesions of the source of 5-HT to the nPGi (the vlPAG) and examined sexual behavior. Removing the source of 5-HT to the nPGi facilitated genital reflexes, but not other aspects of sexual behavior, consistent with our hypothesis. Namely, 5-HT lesions produced a significant increase in the mean number of ejaculations and a significant decrease in ejaculation latency as compared to sham lesioned animals, while latency to mating and the post-ejaculatory interval did not differ. These data suggest that the serotonergic vlPAG-nPGi pathway is an important regulatory mechanism for the inhibition of ejaculation in rats and supports the hypothesis that this circuit contributes to SSRI-induced inhibition of ejaculation.
Topics: Animals; Immunohistochemistry; Male; Periaqueductal Gray; Rats; Rats, Sprague-Dawley; Serotonin; Sexual Behavior, Animal
PubMed: 21296106
DOI: 10.1016/j.pbb.2011.01.024 -
Actas Espanolas de Psiquiatria 2010Treatment with neuroleptics may be associated with secondary sexual dysfunction. Studies of sexual dysfunction induced by antipsychotic are important to establish the...
INTRODUCTION
Treatment with neuroleptics may be associated with secondary sexual dysfunction. Studies of sexual dysfunction induced by antipsychotic are important to establish the effectiveness of these agents in patients taking chronic treatments. The main objective of this study was to evaluate prospectively whether a 3 month course ofaripiprazole produces changes in the sexual function of patients with schizophrenia.
METHODS
The efficacy analysis was performed in the intention-to-treat population (41 patients) and the per protocol population (36 patients). The safety analysis was based on the total sample (42 patients).
RESULTS
The incidence of sexual dysfunction after 3 months of treatment with aripiprazole was zero both in patients who switched therapy due to lack of efficacy and in those taking aripiprazole as a first antipsychotic. Aripiprazole led to an improvement in the symptoms of psychosis (score on the BPRS) and lower scores on the SALSEX questionnaire.The most remarkable improvement was in delayed eyaculation/orgasm.
CONCLUSION
During the 3 months of treatment, we observed an overall improvement in sexual performance, with a quicker recovery in men than in women, although recovery was similar in both at the end of treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Sexual Dysfunction, Physiological; Time Factors; Young Adult
PubMed: 20931406
DOI: No ID Found -
Drug, Healthcare and Patient Safety 2010Sexual dysfunction is a common side effect of antidepressants and can have significant impact on the person's quality of life, relationships, mental health, and...
Sexual dysfunction is a common side effect of antidepressants and can have significant impact on the person's quality of life, relationships, mental health, and recovery. The reported incidence of sexual dysfunction associated with antidepressant medication varies considerably between studies, making it difficult to estimate the exact incidence or prevalence. The sexual problems reported range from decreased sexual desire, decreased sexual excitement, diminished or delayed orgasm, to erection or delayed ejaculation problems. There are a number of case reports of sexual side effects, such as priapism, painful ejaculation, penile anesthesia, loss of sensation in the vagina and nipples, persistent genital arousal and nonpuerperal lactation in women. The focus of this article is to explore the incidence, pathophysiology, and treatment of antidepressant iatrogenic sexual dysfunction.
PubMed: 21701626
DOI: 10.2147/DHPS.S7634 -
The Journal of Sexual Medicine Nov 2008Male circumcision is being promoted for HIV prevention in high-risk heterosexual populations. However, there is a concern that circumcision may impair sexual function. (Randomized Controlled Trial)
Randomized Controlled Trial
INTRODUCTION
Male circumcision is being promoted for HIV prevention in high-risk heterosexual populations. However, there is a concern that circumcision may impair sexual function.
AIM
To assess adult male circumcision's effect on men's sexual function and pleasure.
METHODS
Participants in a controlled trial of circumcision to reduce HIV incidence in Kisumu, Kenya were uncircumcised, HIV negative, sexually active men, aged 18-24 years, with a hemoglobin >or=9.0 mmol/L. Exclusion criteria included foreskin covering less than half the glans, a condition that might unduly increase surgical risks, or a medical indication for circumcision. Participants were randomized 1:1 to either immediate circumcision or delayed circumcision after 2 years (control group). Detailed evaluations occurred at 1, 3, 6, 12, 18, and 24 months.
MAIN OUTCOME MEASURES
(i) Sexual function between circumcised and uncircumcised men; and (ii) sexual satisfaction and pleasure over time following circumcision.
RESULTS
Between February 2002 and September 2005, 2,784 participants were randomized, including the 100 excluded from this analysis because they crossed over, were not circumcised within 30 days of randomization, did not complete baseline interviews, or were outside the age range. For the circumcision and control groups, respectively, rates of any reported sexual dysfunction decreased from 23.6% and 25.9% at baseline to 6.2% and 5.8% at month 24. Changes over time were not associated with circumcision status. Compared to before they were circumcised, 64.0% of circumcised men reported their penis was "much more sensitive," and 54.5% rated their ease of reaching orgasm as "much more" at month 24.
CONCLUSIONS
Adult male circumcision was not associated with sexual dysfunction. Circumcised men reported increased penile sensitivity and enhanced ease of reaching orgasm. These data indicate that integration of male circumcision into programs to reduce HIV risk is unlikely to adversely effect male sexual function.
Topics: Adolescent; Circumcision, Male; Developing Countries; Follow-Up Studies; HIV Infections; Humans; Kenya; Male; Postoperative Complications; Prospective Studies; Sexual Behavior; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Young Adult
PubMed: 18761593
DOI: 10.1111/j.1743-6109.2008.00979.x -
Tidsskrift For Den Norske Laegeforening... Feb 2008Sexuality is an important part of most men's quality of life. Reduced sexual function is common and can be treated. (Review)
Review
BACKGROUND
Sexuality is an important part of most men's quality of life. Reduced sexual function is common and can be treated.
MATERIAL AND METHODS
The article is based on relevant publications retrieved from Medline, recent textbooks and the authors' clinical experience.
RESULTS AND INTERPRETATION
Numerous aspects affect sexual function in men. The following is discussed; prevalence of sexual dysfunction in men, symptoms, diagnostic approaches and treatment options for premature ejaculation, delayed ejaculation, anejaculation, retrograde ejaculation, erectile dysfunction with organic cause, congenital penile curvature, Peyronie's disease, reduced sexual desire and hypogonadism. Medical doctors need to know about sexual medicine and to be able to communicate well with patients about these issues.
Topics: Ejaculation; Erectile Dysfunction; Humans; Hypogonadism; Libido; Male; Orgasm; Penis; Physician-Patient Relations; Sexual Dysfunction, Physiological; Sexuality
PubMed: 18274579
DOI: No ID Found -
Asian Journal of Andrology Jan 2008In humans androgen decline is presented as a clinical picture which includes decreased sexual interest, diminished erectile capacity, delayed or absent orgasms and... (Review)
Review
In humans androgen decline is presented as a clinical picture which includes decreased sexual interest, diminished erectile capacity, delayed or absent orgasms and reduced sexual pleasure. Additionally, changes in mood, diminished well being, fatigue, depression and irritability are also associated with androgen insufficiency. The critical role of androgens on the development, growth, and maintenance of the penis has been widely accepted. Although, the exact effect of androgens on erectile physiology still remains undetermined, recent experimental studies have broaden our understanding about the relationship between androgens and erectile function. Preclinical studies showed that androgen deprivation leads to penile tissue atrophy and alterations in the nerve structures of the penis. Furthermore, androgen deprivation caused to accumulation of fat containing cells and decreased protein expression of endothelial and neuronal nitric oxide synthases (eNOS and nNOS), and phosphodiesterase type-5 (PDE-5), which play crucial role in normal erectile physiology. On the light of the recent literature, we aimed to present the direct effect of androgens on the structures, development and maintenance of penile tissue and erectile physiology as well. Furthermore, according to the clinical studies we conclude the aetiology, pathophysiology, prevalence, diagnosis and treatment options of hypogonadism in aging men.
Topics: Aging; Androgens; Erectile Dysfunction; Humans; Hypogonadism; Male; Testosterone
PubMed: 18087642
DOI: 10.1111/j.1745-7262.2008.00375.x